News Sentiment

VSTM sentiment intelligence

Verastem Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 52 Balanced news tone 55 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 5.53 Week of 10 Jul 2026
Weighted tone 52/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

76/100 classification confidence.

Company focus 47

directly relevant articles

Source quality 0

high-authority source matches

Trend context Trend inactive

+22.9% over one week, +34.9% over four weeks, trend inactive, and near fair-value range.

Latest direct headline Positive

RBC Capital Reaffirms Outperform Rating For Verastem (VSTM)

Market Reaction

Price moving ahead of tone

59/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 76/100 classification
One-week reaction 22.9% Price confirming higher
Trend fit Trend inactive 34.9% over four weeks
Fair value -19.3% Near fair-value range

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 13
Neutral 31
Negative 11

Relevance

Why the article matched

Direct first
Direct company coverage 47
Industry context 8
Sector context 0

Sources

Coverage mix

Publishers
Market source 11
TradingView 10
Stock Titan 8
simplywall.st 6
Investing.com 4
Insider Monkey 3
GuruFocus 2
MT Newswires 2

Event Lens

What the news is about

Classified themes
Market update 24
Earnings 18
Analyst action 9
Regulatory and legal 2
Guidance 1
Deals and strategy 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 55
Yahoo! Finance Canada Direct company coverage

RBC Capital Reaffirms Outperform Rating For Verastem (VSTM)

RBC Capital has reaffirmed its Outperform rating for Verastem Inc. (VSTM) and adjusted its price target from $15 to $14, still implying over 211% upside potential. This adjustment follows RBC's Q2 biotech sector preview, which noted strong momentum driven by encouraging data and

Tone
Positive 78/100
Event
Analyst action
Published
15 Jul 2026 17:18
Source
Yahoo! Finance Canada
Stock Traders Daily Direct company coverage

Trading the Move, Not the Narrative: (VSTM) Edition

This article analyzes Verastem Inc. (VSTM), highlighting a near- and mid-term strong sentiment with a weak long-term outlook and a mid-channel oscillation pattern. It presents three AI-generated trading strategies (Position, Momentum Breakout, and Risk Hedging) with specific entr

Tone
Positive 71/100
Event
Guidance
Published
13 Jul 2026 21:04
Source
Stock Traders Daily
Stock Titan Direct company coverage

Polar Capital group files 13G/A reporting 3.7M shares in Verastem (VSTM)

Polar Capital group has filed a 13G/A, disclosing beneficial ownership of 3.7 million shares in Verastem, Inc. (VSTM), which represents a 4.80% stake in the company. The filing indicates sole voting and dispositive power over these shares for the group, consisting of Polar Capita

Tone
Neutral 50/100
Event
Deals and strategy
Published
08 Jul 2026 13:39
Source
Stock Titan
Moomoo Direct company coverage

RBC Capital Maintains Verastem(VSTM.US) With Buy Rating, Cuts Target Price to $14

RBC Capital has reaffirmed its Buy rating on Verastem (VSTM.US) but has reduced its target price to $14. This adjustment suggests a continued positive outlook on the company despite the lower price target, indicating potential confidence in its long-term prospects.

Tone
Positive 65/100
Event
Analyst action
Published
07 Jul 2026 22:04
Source
Moomoo
AD HOC NEWS Direct company coverage

Verastem Inc outlines oncology focus as investors weigh long-term prospects

Verastem Inc, an oncology-focused biotech company, is developing targeted cancer therapies, and its long-term prospects are being assessed by investors. The company operates in a high-risk, high-potential segment of the healthcare sector, where clinical data and regulatory decisi

Tone
Positive 61/100
Event
Regulatory and legal
Published
07 Jul 2026 20:10
Source
AD HOC NEWS
marketscreener.com Direct company coverage

RBC Capital Adjusts Verastem Price Target to $14 From $15, Maintains Outperform Rating

RBC Capital has adjusted its price target for Verastem (VSTM) to $14, down from $15, while reaffirming an Outperform rating on the stock. Verastem is a late-stage biopharmaceutical company focused on developing therapies for RAS/MAPK pathway-driven cancers, with product candidate

Tone
Neutral 50/100
Event
Analyst action
Published
07 Jul 2026 12:10
Source
marketscreener.com
Insider Monkey Direct company coverage

Here’s What RBC Capital Has to Say About Verastem (VSTM)

RBC Capital has reiterated an Outperform rating on Verastem (VSTM) with a $15 price target, driven by the potential of the company's G12D inhibitor drug program targeting specific genetic mutations in cancers. While acknowledging risks and some safety profile improvement potentia

Tone
Positive 70/100
Event
Analyst action
Published
03 Jul 2026 13:10
Source
Insider Monkey
Market source Direct company coverage

Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Verastem Oncology announced the grant of 399,750 restricted stock units and 91,000 stock options to new employees. These grants were made under the Nasdaq inducement grant exception as an incentive for accepting employment with the company. The stock options have an exercise pric

Tone
Neutral 50/100
Event
Market update
Published
03 Jul 2026 08:39
Source
Market source
GuruFocus Direct company coverage

VSTM Maintained by BTIG -- Price Target Unchanged at $18.00

BTIG has maintained a "Buy" rating on Verastem (VSTM) with an unchanged price target of $18.00, signaling confidence despite the company's low GF Score™ of 11/100, which indicates significant financial and profitability challenges. While analysts see potential upside from the cur

Tone
Positive 61/100
Event
Analyst action
Published
02 Jul 2026 18:52
Source
GuruFocus
TradingView Direct company coverage

Enterprise value to EBIT forward of Verastem, Inc. – NASDAQ:VSTM

This article provides an analysis of the enterprise value to EBIT forward for Verastem, Inc. (NASDAQ:VSTM), indicating financial metrics from sources like ICE Data Services and FactSet. The content is presented within the TradingView platform, focusing on the company's financial

Tone
Neutral 50/100
Event
Market update
Published
01 Jul 2026 19:42
Source
TradingView
Insider Monkey Direct company coverage

Verastem (VSTM) Shares Encouraging Results from VS-7375 Phase 1/2 Trial

Verastem Inc. (NASDAQ: VSTM) has released encouraging initial findings from its TARGET-D 101 Phase 1/2 trial for VS-7375, an experimental oral KRAS G12D inhibitor. The drug demonstrated positive clinical activity and a good safety profile across various dosage levels and tumor ty

Tone
Positive 73/100
Event
Earnings
Published
30 Jun 2026 16:09
Source
Insider Monkey
TradingView Direct company coverage

Verastem, Inc. Actuals & Estimates (SWB:2VSA)

This article provides an overview of Verastem, Inc. (SWB:2VSA) financial actuals and analyst estimates, including income statement, balance sheet, and cash flow data. It also covers analyst price targets, historical stock performance, upcoming earnings dates, and key financial me

Tone
Neutral 50/100
Event
Earnings
Published
27 Jun 2026 08:39
Source
TradingView
TradingView Direct company coverage

Verastem, Inc. Actuals & Estimates (NASDAQ:VSTM)

This article provides an overview of Verastem, Inc. (NASDAQ:VSTM) stock, including its current price, historical performance, analyst forecasts, and financial data. It highlights the company's financial actuals and estimates for the income statement, balance sheet, and cash flow,

Tone
Negative 37/100
Event
Analyst action
Published
26 Jun 2026 14:09
Source
TradingView
TradingView Direct company coverage

Price to earnings forward of Verastem, Inc. – NASDAQ:VSTM

This article displays financial data for Verastem, Inc. (NASDAQ: VSTM), specifically its price-to-earnings forward metric. The content appears to be a stub or a placeholder from TradingView, indicating where this financial information would typically be presented, though no actua

Tone
Neutral 50/100
Event
Earnings
Published
26 Jun 2026 13:09
Source
TradingView
TradingView Direct company coverage

VSTM Forecast — Price Target — Prediction for 2027

This article provides a forecast for Verastem, Inc. (VSTM) stock, including analyst price targets, current stock performance, and key financial metrics. It highlights a max price estimate of $18.00 and a min estimate of $8.00 from analysts, alongside details on its current tradin

Tone
Negative 39/100
Event
Analyst action
Published
26 Jun 2026 09:10
Source
TradingView
Investing.com Direct company coverage

Verastem CFO Daniel Calkins sells $17,089 in company stock

Verastem CFO Daniel Calkins sold $17,089 worth of company stock on June 22, 2026, to cover tax withholding requirements related to restricted stock unit vesting. Following the sale of 4,089 shares, Calkins still directly owns 117,238 shares of VSTM. This transaction comes as the

Tone
Positive 65/100
Event
Market update
Published
25 Jun 2026 22:04
Source
Investing.com
TradingView Direct company coverage

Price to book forward of Verastem, Inc. – NASDAQ:VSTM

This article provides financial information for Verastem, Inc. (NASDAQ: VSTM), specifically focusing on its forward price-to-book ratio. It appears to be a financial data snippet from a platform like TradingView, offering a snapshot of a particular metric for the company. The con

Tone
Neutral 50/100
Event
Market update
Published
25 Jun 2026 20:41
Source
TradingView
Stock Titan Direct company coverage

Verastem (VSTM) insider sale notice: 21,492 shares reported for resale

Verastem Inc. has filed a Form 144 notice for the proposed resale of 21,492 shares of common stock by insider Robert Gagnon. These shares originated from vested Restricted Stock Units dated December 15, 2021. The filing also indicates that Gagnon sold 20,103 shares in the past th

Tone
Neutral 50/100
Event
Market update
Published
25 Jun 2026 19:41
Source
Stock Titan
TradingView Direct company coverage

Verastem, Inc. Actuals & Estimates (GETTEX:2VSA)

This article provides an overview of Verastem, Inc. (2VSA) stock performance, financial data, and analyst forecasts. It covers the current stock price, historical highs and lows, market capitalization, volatility, and upcoming earnings reports. Additionally, it includes answers t

Tone
Negative 39/100
Event
Earnings
Published
25 Jun 2026 18:41
Source
TradingView
TradingView Direct company coverage

Enterprise value to EBITDA forward of Verastem, Inc. – GETTEX:2VSA

This page from TradingView displays financial information for Verastem, Inc. (2VSA on GETTEX), specifically focusing on its Enterprise Value to EBITDA forward metric. The content indicates the market is closed for this stock and no trades have occurred for the displayed period.

Tone
Neutral 50/100
Event
Market update
Published
25 Jun 2026 14:40
Source
TradingView
Insider Monkey Direct company coverage

Is Verastem, Inc. (VSTM)’s KRAS-Targeted Combination Therapy a Breakthrough for Pancreatic Cancer?

Verastem, Inc. (VSTM) is exploring KRAS-targeted combination therapies for pancreatic cancer. Recent updates from the RAMP 205 Phase 1b/2a study demonstrated safety and efficacy findings for a combination therapy in metastatic pancreatic ductal adenocarcinoma, while the TARGET-D

Tone
Positive 70/100
Event
Market update
Published
25 Jun 2026 12:40
Source
Insider Monkey
GuruFocus Direct company coverage

Verastem Inc (VSTM) CEO Dan Paterson Sells 20,871 Shares

Verastem Inc's CEO, Dan Paterson, sold 20,871 shares on June 22, 2026, reducing his holdings to 591,242 shares. This sale is part of a trend over the last year where insiders have only sold shares, with no purchases. Verastem Inc is a biopharmaceutical company focused on cancer t

Tone
Negative 31/100
Event
Market update
Published
25 Jun 2026 06:40
Source
GuruFocus
Stock Titan Direct company coverage

Verastem (VSTM) CEO sells 20,871 shares to cover RSU tax withholding

Verastem, Inc. President and CEO Dan Paterson sold 20,871 shares of common stock at $4.18 per share. This sale was conducted to cover statutory withholding taxes related to the vesting of restricted stock units, not for discretionary trading. Following the transaction, Paterson d

Tone
Neutral 50/100
Event
Market update
Published
25 Jun 2026 04:04
Source
Stock Titan
Investing.com South Africa Direct company coverage

Form 4 Verastem Inc For: 24 June By Investing.com

This article from Investing.com reports on a Form 4 filing for Verastem Inc., related to activities on June 24th. The article is very brief, providing only the filing information and a stock price change for VSTM. It includes various market data and popular articles as typical pl

Tone
Neutral 50/100
Event
Market update
Published
25 Jun 2026 02:40
Source
Investing.com South Africa
Stock Titan Direct company coverage

Verastem (NASDAQ: VSTM) CFO sells 4,089 shares to cover RSU taxes

Verastem, Inc.'s CFO, Daniel Calkins, sold 4,089 shares of common stock on June 22, 2026, in two tranches at $4.13 and $4.18 per share. These sales were not discretionary but were made to satisfy statutory tax withholding requirements related to the vesting of restricted stock un

Tone
Negative 41/100
Event
Market update
Published
24 Jun 2026 21:11
Source
Stock Titan